fbpx

Other Relevant News

United Nations approves WHO recommendation to reschedule cannabis in historic vote

Marijuana Business Daily, December 2, 2020

The United Nations Commission on Narcotic Drugs (CND) accepted a World Health Organization (WHO) recommendation to remove cannabis and cannabis resin from Schedule IV of the 1961 Single Convention on Narcotic Drugs.

Psilocybin Treatment for Mental Health Gets Legal Framework

Scientific American, December 1, 2020

Oregon became the first state to legalise therapeutic use of the drug, as new research affirms its benefits for treating depression.

Jewish psychedelics advocate working to turn drug into legal medicine

The Jerusalem Post, November 20, 2020

In the United States, research on these chemicals has been banned since the 1960s because, in the government’s judgment, they have no recognized medical value.

'The war on drugs failed': California lawmaker will push to decriminalise psychedelics

The Guardian, November 20, 2020

A California lawmaker has announced he will take on the arduous battle to decriminalize psychedelics in the state, citing Oregon, which voted to decriminalize hard drugs and legalize psilocybin, and the District of Columbia, which has decriminalized psychedelics, as inspiration.

Psilocybin for Depression Study Approved and Funded by German Government

Psilocybin Alpha., November 19, 2020

The German Government has approved a Phase 2b study on psilocybin for treatment-resistant depression, and is providing millions of Euros to this latest psychedelic research project.

U.S. Department of Defense’s Defense Advanced Research Projects Agency (DARPA) has invested nearly USD $27 million into a team of researchers led by professor of pharmacology Dr. Bryan L. Roth at the University of North Carolina School of Medicine

The Dales Report, November 11, 2020

The U.S. Department of Defense’s Defense Advanced Research Projects Agency (DARPA) has invested nearly USD $27 million into a team of researchers led by professor of pharmacology Dr. Bryan L. Roth at the University of North Carolina School of Medicine.

Washington, DC, just decriminalized psychedelic plants. Here’s what happens next

Leafly, November 4, 2020

Residents of the nation’s capital just took a step toward more liberal use of hallucinogens, in response to a groundswell of interest in new drugs for medical maladies. Initiative 81, the Entheogenic Plants and Fungus Policy Act of 2020, makes certain psychedelic drug crimes the “lowest enforcement priority” of the District’s Metropolitan Police Department.

Oregon becomes first state to legalize magic mushrooms as more states ease drug laws in ‘psychedelic renaissance’

CNBC, November 4, 2020

Oregon on Wednesday became the first state to legalize the active ingredient in so-called magic mushrooms on an election night that saw more states ease restrictions on drugs across the country.

Oregon Measure 109, Psilocybin Mushroom Services Program Initiative (2020)

Ballotpedia, November 3, 2020

Oregon Measure 109, the Psilocybin Program Initiative was on the ballot in Oregon as an initiated state statute on November 3, 2020. It was approved. Learn more here.

Re-examining Cultural Beliefs Around Children and Psychedelics

Psychedelics Today, October 26, 2020

The subject of children and psychedelics is one of great contention, often considered an untouchable, “no-go zone” by many in Western society. Nonetheless, we now find ourselves in the midst of a psychedelic renaissance...

Forbes: Numinus Becomes The First Canadian Psychedelics Company To Legally Harvest Magic Mushrooms

Forbes, October 23, 2020

A Vancouver-based psychedelics company has become the first in Canada to complete a legal harvest of magic mushrooms since the last wave of psychedelic research ended there in the 1970s.

Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD

MAPS, October 14, 2020

Healthcare cost savings of MDMA-assisted psychotherapy for PTSD estimated to be greater than $(USD)103.2 million with a return of 5,553 Quality of Life Years per 1,000 patients.

The New Yorker: Turn On, Tune In, Get Well

The New Yorker, 12 October, 2020

New York is getting its first psychedelic-medicine center, with the help of a startup called MindMed, which develops hallucinogens to treat mental illness and addiction, and is funding an institute at N.Y.U. Langone Medical Center

What if a Pill Can Change Your Politics or Religious Beliefs?

Scientific America, 11 October, 2020

A new mental health treatment using the psychedelic compound psilocybin raises questions about medicine and values.

PsyTech Hosts Live Investor Conference & Webinar October 27, 2020 and Closes Transaction with One of the Largest Psychedelic Conferences PsyTech.biz

Globe News Wire, 25 September, 2020

PsyTech Summit 2020 will be a one-day, international event bringing together decision makers, investors, clinicians, thought leaders, and advocates for the purpose of advancing psychedelics science, business, and reform. Mind Medicine Australia Executive Director, Tania de Jong AM will be presenting alongside other distinguished speakers associated with Mind Medicine Australia including Professor David Nutt, Dr Rick Doblin, Professor Matthew W. Johnson, Dr Robin Carhart-Harris, Dr Adele Lafrance and Dr Reid Robison.

The Washington Post: Who Will Benefit From Psychedelic Medicine?

Washington Post, September 21, 2020

Who Will Benefit From Psychedelic Medicine? These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.

Mind Medicine CEO Calls Compass IPO: A 'Clear Bellwether' For Psychedelic Space

Bezinga, September 19, 2020

On Friday, UK-based mental health care company Compass Pathways NASDAQCMPS announced it has begun trading on NASDAQ under the symbol CMPS. This is the first time a psychedelics company is listed on a major U.S. Stock Exchange.

UC Berkeley launches center for psychedelic science and education

Berkeleyside, September 18, 2020

UC Berkeley launches center for psychedelic science and education With $1.25M in seed funding, the new center will conduct research using psychedelics to investigate cognition, perception and emotion and their biological bases in the human brain.

IntelGenx inks double deals to develop oral film psychedelics for psychiatric use

Fierce Pharma, September 16, 2020

Drug delivery specialist IntelGenx has penned two deals to develop film-based, prescription psychedelics amid a surge of interest—and investment—from the biopharma industry.

Usona Puts New Psilocybin Synthesis Method in the Public Domain

Ann Harrison, Lucid.news, September 15, 2018

The nonprofit Usona Institute has developed a new technique to synthesize kilograms of pharmaceutical grade psilocybin and placed this information in the public domain where it cannot be patented.
Download the article here as PDF.

Psychedelics For CNS Disorders: Understanding The Opportunity

Ben Comer, Pharma Intelligence, September 9, 2018

Investigational uses of psilocybin and MDMA – two illicit drugs associated with recreational use and abuse in the US – will soon enter the later stages of clinical development for the treatment of CNS disorders including depression, addiction and post-traumatic stress disorder.
Download the article here as PDF.

Breaking the stigma: Psychedelic Drugs

Cannabis Life Network, August 22, 2020

There are a lot of negative stigma surrounding psychedelic drugs. A large portion of the population and the government condemn these substances to be dangerous, addictive, and illegal. Although, that may be true when it comes to opiates or stimulants (such as heroin or cocaine). As they are, indeed, physiologically toxic and addictive. Psychedelics, on the other hand, have been mistaken to have the same, or even worse detrimental effects to one’s health.

Silicon Valley and Wall Street Elites Pour Money Into Psychedelic Research

The Wall Street Journal, August 20, 2020

A group of Silicon Valley and Wall Street executives has raised $30 million to speed the development of a closely watched psychedelic-drug therapy using the key ingredient of the party drug Ecstasy to treat trauma patients.

Psychedelic Science in Post-Covid Psychiatry

DocWire News, August 19, 2020

The medium to long term consequences of COVID-19 are not yet known, though an increase in mental health problems are predicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19.

Eleusis sheds light on psychedelics that relieve asthma in rats with no mental effects

Fierce Biotech, August 13, 2020

Psychedelic drugs like LSD have long been of interest in the medical community because of their anti-inflammatory properties. But efforts to transform them into therapeutics have been hampered by laws restricting the use of psychedelics, not to mention the stigma associated with them.

The first Canadian to legally consume psilocybin for medical purposes shares his experience

Regina Leader-Post, Aug 21, 2020

Earlier this month, four Canadians received Section 56 exemption to the Controlled Drugs and Substances Act, allowing them to pursue psilocybin therapy for end-of-life distress.

Canada Will Let Terminally Ill Patients Use Psychedelic Mushrooms For End-Of-Life Care

CNN, August 6, 2020

Four cancer patients in end-of-life care will be become the first people in decades to legally possess and consume psilocybin mushrooms in Canada after a landmark decision.

The Current Status of Psychedelics in Psychiatry

Dr David Nutt and Dr Robin Carhart-Harris, American Medical Association, July 29, 2020

Download the article here as PDF.

Psilocybin Therapy for Addiction

60 Minutes USA, July 21, 2020

Anderson Cooper sits down with Jon Kostakopoulos to discuss his experience as a clinical participant in an NYU psilocybin study treating alcohol use disorder.

Psilocybin & OCD: Can psychedelics treat obsessive compulsive disorder?

New Atlas, July 23, 2020

A new review from neuroethicist Eddie Jacobs, and published in the Journal of Psychedelic Studies, is suggesting psilocybin may have great potential as a treatment for obsessive-compulsive disorder (OCD).

Lucy in the sky with diamonds

Vogue, July 20, 2020

LSD, psilocybin, ecstasy, ayahuasca. From happy trips of the past to mental health of the present, could psychedelics be the future of therapy?

Magic mushrooms could help ex-soldiers to overcome trauma

The Guardian, July 4, 2020

As more troops self-medicate with psychedelic drugs to help with PTSD, a group of experts lobby for proper clinical trials.

We can no longer ignore the potential of psychedelic drugs to treat depression

Dr Robin Carhart-Harris, The Guardian, June 8, 2020

Imperial College, UK have been comparing psilocybin to conventional antidepressants – and the results are likely to be game-changing

Dr Robin Carhart-Harris is a member of the Mind Medicine Australia advisory panel.

COVID-19 impact likely to lead to increased rates of suicide and mental health

Dr Tony Bartone, Professor Ian Hickie AM, Professor Patrick McGorry AO, AMA Joint Statement, June 2, 2020

Australia will likely see increases in youth suicide and a surge in demand for specialist mental health services as the full and lasting impact of the COVID-19 pandemic is experienced across the community.

Psychedelics v. Cannabis: In Search of a Better Business Plan

David H., The Cannabis Investor, May 27, 2020

Organizations forming today will build the infrastructure which, three to five years from now, will be delivering psychedelic medicines to the world.

Interim Analysis Shows At Least 90% Chance of Statistically Significant Difference in PTSD Symptoms after MDMA-assisted Psychotherapy

Brad Burge, Multidisciplinary Association for Psychedelic Studies (MAPS), May 13, 2020

Results are the strongest confirmation that an interim analysis can provide

German Government Funds Psilocybin Study for Depression

Mind and Brain Institute, April, 2020

Move over, pot: Psychedelic companies are about to go public

Kristine Owram, Bloomberg News, February 11, 2020

Psychedelics Create New Communication Pathways In The Brain ( Homological Scaffolds )

Beckley Foundation, November 17, 2017

Watch our brains become more connected on psilocybin, and learn how psychedelics can help treat conditions such as depression, addiction, and PTSD.

The future of psychedelic science: What the next decade holds

Rich Haridy, New Atlas, December 26, 2019

The Return Trip: Psychedelics may come back from the abyss of illegality

Peter Stilla, Valley Advocate, November 20, 2019

Psilocybin-assisted therapy for depression: How do we advance the field?

David Castle, Australian & New Zealand Journal of Psychiatry, November 19, 2019

Magic mushroom compound psilocybin shows promise for treatment of anxiety and depression

Robyn Williams, The Science Show, ABC Radio National, November 11, 2019

Health Report with Norman Swan

Dr Norman Swan, On Breakfast Program with Hamish Macdonald, ABC Radio National, November 11, 2019

Research into psychedelic drugs like LSD is growing, encouraged by positive early trials. Scientists think these drugs could treat things like post-traumatic stress disorder and depression.

Download the interview here as an mp3.

What Happened When I Sought Alternative Mental Health Treatment Abroad

Lizbeth Finn-Arnold, The Mighty, November 11, 2019

Why Psychedelics Could be the Future of Anorexia Treatment

Tessa Love, Elemental Medium, November 6, 2019

Tim Ferris, the man who put his money behind psychedelic medicine

Benedict Carey, The New York Times, September 9, 2019

John Hopkins opens new center for Psychedelic Research

Benedict Carey, The New York Times, September 5, 2019

Israel seeks to beat PTSD with ‘ecstasy’ therapy

Jonah Mandel, The Times of Isreal, August 21, 2019

MDMA, Or Ecstasy, Shows Promise As A PTSD Treatment

Will Stone, WAMU 88.5 American University Radio, June 13, 2019

'These are healing plants': Oakland decriminalizes magic mushrooms

Sam Levin, The Guardian, June 5, 2019
Yesterday Oakland became the second city in the US to decriminalize magic mushrooms and other psychedelics.

Denver Voters Support ‘Magic’ Mushrooms

By Patricia Mazzei, The New York Times, May 8, 2019

1 in 8 (over 3 million) Australians are on antidepressants - Why is the Lucky Country so miserable?

By Dr Martin Whitely and Dr Melissa Raven, PsychWatch Australia, February 10, 2019

Israel approves compassionate use of MDMA to treat PTSD

Science & Health - Haaretz.com, February 10, 2019

Denver could become the first US city to decriminalize magic mushrooms

By Mallory Hughes and Jacqueline Howard, CNN. Updated 2102 GMT (0502 HKT) January 9, 2019

MDMA—its potential therapeutic use podcast extra

All in the Mind, ABC Radio National, September 10, 2018

Turn on, tune in

All in the Mind, ABC Radio National, September 9, 2018

Finding Peace With the Fact I Would Die

Nick Fernandez, Medium, May 30, 2018

Podcast extra - MDMA and its potential therapeutic use

All in the Mind, ABC Radio National, March 22, 2018

Johns Hopkins and NYU studies in psilocybin as a treatment for cancer-related psychological distress. ​

News outlets included CNNNew York Times, NewsweekPBS NewshourScienceScientific AmericanThe AtlanticThe GuardianTimeand USA Todayamong others.
Two clinical studies (released Dec. 1, 2016) examining the effect of psilocybin on symptoms of depression and anxiety in people with life-threatening cancer were released and covered by a number of media.

“The fascinating, strange medical potential of psychedelic drugs, explained in 50+ studies"

Vox June 27, 2016
Show Me the Evidence staff examines more than 50 studies analyzing the safety and efficacy of psychedelic drugs and psychedelic-assisted therapy and interviews researchers involved in the work. Vox, 2016

"Magic-mushroom drug lifts depression in first human trial"

Zoe Cormier, Nature, May 17, 2016
Imperial College study provides preliminary support for the safety and efficacy of psilocybin as a therapy for treatment-resistant depression. Nature, 2016

“Psilocybin can reduce the pain of social exclusion”

Douglas Main, Newsweek, April 19, 2016
Researchers at the University of Zurich show that a small amount of psilocybin can reduce the distress caused by mild social exclusion and lessens activity in the area of the brain associated with this emotion. Newsweek, 2016

“Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA”

The Lancet Psychiatry, April 5, 2016
Drug-assisted psychotherapy as a possible alternative to existing pharmacological and psychological treatments. (Free registration required)

“Professor Probes Psychedelic Drugs for a Cure to Nicotine Addiction”

Washingtonian, January 7, 2014
Recent John’s Hopkins study on effecting addictive behaviour with psychedelics. Washingtonian, 2014

Close Menu